-
Je něco špatně v tomto záznamu ?
Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant
S. Tsujino, S. Deguchi, T. Nomai, M. Padilla-Blanco, A. Plianchaisuk, L. Wang, MM. Begum, K. Uriu, K. Mizuma, N. Nao, I. Kojima, T. Tsubo, J. Li, Y. Matsumura, M. Nagao, Y. Oda, M. Tsuda, Y. Anraku, S. Kita, H. Yajima, K. Sasaki-Tabata, Z. Guo,...
Jazyk angličtina Země Austrálie
Typ dokumentu časopisecké články
Grantová podpora
Core Research for Evolutional Science and Technology
NLK
Medline Complete (EBSCOhost)
od 2008-01-01 do Před 1 rokem
Wiley Free Content
od 1997
PubMed
38961765
DOI
10.1111/1348-0421.13165
Knihovny.cz E-zdroje
- MeSH
- antivirové látky farmakologie MeSH
- Cercopithecus aethiops MeSH
- COVID-19 * virologie MeSH
- elektronová kryomikroskopie MeSH
- fylogeneze * MeSH
- glykoprotein S, koronavirus * genetika chemie MeSH
- lidé MeSH
- myši MeSH
- SARS-CoV-2 * genetika MeSH
- Vero buňky MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
In middle to late 2023, a sublineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB, EG.5.1 (a progeny of XBB.1.9.2), is spreading rapidly around the world. We performed multiscale investigations, including phylogenetic analysis, epidemic dynamics modeling, infection experiments using pseudoviruses, clinical isolates, and recombinant viruses in cell cultures and experimental animals, and the use of human sera and antiviral compounds, to reveal the virological features of the newly emerging EG.5.1 variant. Our phylogenetic analysis and epidemic dynamics modeling suggested that two hallmark substitutions of EG.5.1, S:F456L and ORF9b:I5T are critical to its increased viral fitness. Experimental investigations on the growth kinetics, sensitivity to clinically available antivirals, fusogenicity, and pathogenicity of EG.5.1 suggested that the virological features of EG.5.1 are comparable to those of XBB.1.5. However, cryo-electron microscopy revealed structural differences between the spike proteins of EG.5.1 and XBB.1.5. We further assessed the impact of ORF9b:I5T on viral features, but it was almost negligible in our experimental setup. Our multiscale investigations provide knowledge for understanding the evolutionary traits of newly emerging pathogenic viruses, including EG.5.1, in the human population.
1st Medical Faculty at Biocev Charles University Vestec Prague Czechia
AMED CREST Japan Agency for Medical Research and Development Tokyo Japan
Center for iPS Cell Research and Application Kyoto University Kyoto Japan
CREST Japan Science and Technology Agency Kawaguchi Japan
Department of Cancer Pathology Faculty of Medicine Hokkaido University Sapporo Japan
Department of Clinical Laboratory Medicine Graduate School of Medicine Kyoto University Kyoto Japan
Department of Clinical Pathology Faculty of Medicine Suez Canal University Ismailia Egypt
Department of Life Sciences Faculty of Natural Science Imperial College London London UK
Department of Microbiology and Immunology Faculty of Medicine Hokkaido University Sapporo Japan
Faculty of Pharmaceutical Sciences Kyushu University Fukuoka Japan
Global Station for Biosurfaces and Drug Discovery Hokkaido University Sapporo Japan
Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
Graduate School of Frontier Sciences The University of Tokyo Kashiwa Japan
Graduate School of Medicine The University of Tokyo Tokyo Japan
Institute for Chemical Reaction Design and Discovery Hokkaido University Sapporo Japan
Institute for Genetic Medicine Hokkaido University Sapporo Japan
Institute for Vaccine Research and Development Hokkaido University Sapporo Japan
Laboratory of Medical Virology Institute for Life and Medical Sciences Kyoto University Kyoto Japan
Laboratory of Virus Control Research Institute for Microbial Diseases Osaka University Suita Japan
One Health Research Center Hokkaido University Sapporo Japan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019122
- 003
- CZ-PrNML
- 005
- 20241024111553.0
- 007
- ta
- 008
- 241015s2024 at f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/1348-0421.13165 $2 doi
- 035 __
- $a (PubMed)38961765
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a at
- 100 1_
- $a Tsujino, Shuhei $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $1 https://orcid.org/0009000475423785
- 245 10
- $a Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant / $c S. Tsujino, S. Deguchi, T. Nomai, M. Padilla-Blanco, A. Plianchaisuk, L. Wang, MM. Begum, K. Uriu, K. Mizuma, N. Nao, I. Kojima, T. Tsubo, J. Li, Y. Matsumura, M. Nagao, Y. Oda, M. Tsuda, Y. Anraku, S. Kita, H. Yajima, K. Sasaki-Tabata, Z. Guo, AA. Hinay, K. Yoshimatsu, Y. Yamamoto, T. Nagamoto, H. Asakura, M. Nagashima, K. Sadamasu, K. Yoshimura, H. Nasser, M. Jonathan, O. Putri, Y. Kim, L. Chen, R. Suzuki, T. Tamura, K. Maenaka, T. Irie, K. Matsuno, S. Tanaka, J. Ito, T. Ikeda, K. Takayama, J. Zahradnik, T. Hashiguchi, T. Fukuhara, K. Sato, Genotype to Phenotype Japan (G2P‐Japan) Consortium
- 520 9_
- $a In middle to late 2023, a sublineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB, EG.5.1 (a progeny of XBB.1.9.2), is spreading rapidly around the world. We performed multiscale investigations, including phylogenetic analysis, epidemic dynamics modeling, infection experiments using pseudoviruses, clinical isolates, and recombinant viruses in cell cultures and experimental animals, and the use of human sera and antiviral compounds, to reveal the virological features of the newly emerging EG.5.1 variant. Our phylogenetic analysis and epidemic dynamics modeling suggested that two hallmark substitutions of EG.5.1, S:F456L and ORF9b:I5T are critical to its increased viral fitness. Experimental investigations on the growth kinetics, sensitivity to clinically available antivirals, fusogenicity, and pathogenicity of EG.5.1 suggested that the virological features of EG.5.1 are comparable to those of XBB.1.5. However, cryo-electron microscopy revealed structural differences between the spike proteins of EG.5.1 and XBB.1.5. We further assessed the impact of ORF9b:I5T on viral features, but it was almost negligible in our experimental setup. Our multiscale investigations provide knowledge for understanding the evolutionary traits of newly emerging pathogenic viruses, including EG.5.1, in the human population.
- 650 12
- $a SARS-CoV-2 $x genetika $7 D000086402
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a fylogeneze $7 D010802
- 650 12
- $a COVID-19 $x virologie $7 D000086382
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a glykoprotein S, koronavirus $x genetika $x chemie $7 D064370
- 650 _2
- $a antivirové látky $x farmakologie $7 D000998
- 650 _2
- $a Cercopithecus aethiops $7 D002522
- 650 _2
- $a Vero buňky $7 D014709
- 650 _2
- $a elektronová kryomikroskopie $7 D020285
- 650 _2
- $a myši $7 D051379
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Deguchi, Sayaka $u Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- 700 1_
- $a Nomai, Tomo $u Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000337289269
- 700 1_
- $a Padilla-Blanco, Miguel $u First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia $u Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU (UCH-CEU), CEU Universities, Valencia, Spain
- 700 1_
- $a Plianchaisuk, Arnon $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $1 https://orcid.org/0009000424160508
- 700 1_
- $a Wang, Lei $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan
- 700 1_
- $a Begum, Mst Monira $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
- 700 1_
- $a Uriu, Keiya $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Mizuma, Keita $u Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Nao, Naganori $u One Health Research Center, Hokkaido University, Sapporo, Japan $u Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan $u Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan
- 700 1_
- $a Kojima, Isshu $u Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Tsubo, Tomoya $u One Health Research Center, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Li, Jingshu $u Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Matsumura, Yasufumi $u Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- 700 1_
- $a Nagao, Miki $u Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- 700 1_
- $a Oda, Yoshitaka $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan
- 700 1_
- $a Tsuda, Masumi $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan
- 700 1_
- $a Anraku, Yuki $u Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000257310902
- 700 1_
- $a Kita, Shunsuke $u Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan $1 https://orcid.org/000000033969302X
- 700 1_
- $a Yajima, Hisano $u Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan
- 700 1_
- $a Sasaki-Tabata, Kaori $u Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
- 700 1_
- $a Guo, Ziyi $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Hinay, Alfredo A $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Yoshimatsu, Kumiko $u Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000200622753
- 700 1_
- $a Yamamoto, Yuki $u HiLung Inc., Kyoto, Japan
- 700 1_
- $a Nagamoto, Tetsuharu $u HiLung Inc., Kyoto, Japan
- 700 1_
- $a Asakura, Hiroyuki $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Nagashima, Mami $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Sadamasu, Kenji $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Yoshimura, Kazuhisa $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Nasser, Hesham $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan $u Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
- 700 1_
- $a Jonathan, Michael $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
- 700 1_
- $a Putri, Olivia $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Department of Biomedicine, School of Life Sciences, Indonesia International Institute for Life Sciences (i3L), Jakarta, Indonesia
- 700 1_
- $a Kim, Yoonjin $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Department of Life Sciences, Faculty of Natural Science, Imperial College London, London, UK
- 700 1_
- $a Chen, Luo $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
- 700 1_
- $a Suzuki, Rigel $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan
- 700 1_
- $a Tamura, Tomokazu $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u One Health Research Center, Hokkaido University, Sapporo, Japan $u Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000313956610
- 700 1_
- $a Maenaka, Katsumi $u Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan $u Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan $u Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan $u Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan $u Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
- 700 1_
- $a Irie, Takashi $u Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- 700 1_
- $a Matsuno, Keita $u Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan $u One Health Research Center, Hokkaido University, Sapporo, Japan $u Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan $u International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Tanaka, Shinya $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan
- 700 1_
- $a Ito, Jumpei $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Graduate School of Medicine, The University of Tokyo, Tokyo, Japan $u International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Ikeda, Terumasa $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan $1 https://orcid.org/0000000328699450
- 700 1_
- $a Takayama, Kazuo $u Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan $u AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan $1 https://orcid.org/0000000211322457
- 700 1_
- $a Zahradnik, Jiri $u First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia
- 700 1_
- $a Hashiguchi, Takao $u Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan $u CREST, Japan Science and Technology Agency, Kawaguchi, Japan
- 700 1_
- $a Fukuhara, Takasuke $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u One Health Research Center, Hokkaido University, Sapporo, Japan $u Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan $u AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan $u Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Japan $1 https://orcid.org/0000000154718331
- 700 1_
- $a Sato, Kei $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Graduate School of Medicine, The University of Tokyo, Tokyo, Japan $u Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan $u International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan $u International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan $1 https://orcid.org/0000000344311380
- 710 2_
- $a Genotype to Phenotype Japan (G2P‐Japan) Consortium
- 773 0_
- $w MED00003343 $t Microbiology and immunology $x 1348-0421 $g Roč. 68, č. 9 (2024), s. 305-330
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38961765 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111546 $b ABA008
- 999 __
- $a ok $b bmc $g 2201757 $s 1231095
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 68 $c 9 $d 305-330 $e 20240704 $i 1348-0421 $m Microbiology and immunology $n Microbiol Immunol $x MED00003343
- GRA __
- $p Core Research for Evolutional Science and Technology
- LZP __
- $a Pubmed-20241015
